360-60-1

Usage

Uses

Used in Polymer Production:
2,3-Diaminobenzotrifluoride 97% is used as a monomer in the production of polymers for various applications, such as plastics, coatings, and adhesives. Its strong nucleophilic properties allow for easy incorporation into polymer chains, enhancing their properties and performance.
Used in Pharmaceutical Industry:
2,3-Diaminobenzotrifluoride 97% is used as an intermediate in the synthesis of pharmaceutical compounds. Its versatility as a building block enables the development of new drugs with improved efficacy and reduced side effects.
Used in Dye Synthesis:
2,3-Diaminobenzotrifluoride 97% is used as a starting material in the synthesis of dyes for various applications, such as textiles, inks, and pigments. Its strong nucleophilic properties facilitate the formation of diverse dye structures with unique color properties.
Used in Agrochemical Production:
2,3-Diaminobenzotrifluoride 97% is used as a key component in the synthesis of agrochemicals, such as pesticides and herbicides. Its reactivity and stability contribute to the development of effective and environmentally friendly agrochemicals.
Used in Metal Chelation:
2,3-Diaminobenzotrifluoride 97% is used as a chelating agent for metal ions in various applications, such as water treatment, metal recovery, and analytical chemistry. Its strong nucleophilic properties enable the formation of stable metal complexes, enhancing the efficiency of metal chelation processes.
Used in Organic Synthesis:
2,3-Diaminobenzotrifluoride 97% is used as a reagent in organic synthesis reactions, such as nucleophilic substitutions and condensation reactions. Its strong nucleophilic properties make it a valuable tool for the synthesis of a wide range of organic compounds.

Upstream product

• 386-71-0 2-nitro-3-(trifluoromethyl)aniline 
• 24821-19-0 2-Nitro-6-trifluormethyl-benzamid 
• 603-11-2 3-nitrophthalic acid 

Downstream Products

• 392-11-0 4-(trifluoromethyl)-1H-benzo[d]imidazole 
• 343-19-1 N,N'-(3-trifluoromethyl-o-phenylene)-bis-acetamide 
• 384-32-7 2-methyl-4-(trifluoromethyl)-1H-benzo[d]imidazole 
• 389-61-7 5-trifluoromethyl-2,3-diphenylquinoxaline 
• 1225652-14-1 E,Z-N₁-(4-bromobenzylidene)-3-(trifluoromethyl)benzene-1,2-diamine 
• 1221265-54-8 2-(3-methoxyphenyl)-3-methyl-5-(trifluoromethyl)quinoxaline 
• 1221265-55-9 3-(3-methoxyphenyl)-2-methyl-5-(trifluoromethyl)quinoxaline 
• 1221265-61-7 2-(4-methoxyphenyl)-5-(trifluoromethyl)-quinoxaline 
• 1221265-62-8 2-(4-methoxyphenyl)-8-(trifluoromethyl)-quinoxaline 
• 1221265-59-3 4-[3-ethyl-5-(trifluoromethyl)quinoxalin-2-yl]phenol 
• 1221265-60-6 C₁₇H₁₃F₃N₂O 
• 1221265-57-1 2-(4-chlorophenyl)-3-methyl-5-(trifluoromethyl)quinoxaline 
• 1221265-58-2 3-(4-chlorophenyl)-2-methyl-5-(trifluoromethyl)quinoxaline 

Relevant academic research and scientific papers

SUBSTITUTED BENZIMIDAZOLE CARBOXAMIDES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS

The invention provides substituted benzimidazole carboxamides and related compounds, compositions containing such compounds, medical kits, and methods for using such compounds and compositions to treat a medical disorder, e.g., cancer, lysosomal storage disorder, neurodegenerative disorder, inflammatory disorder, in a patient.

TREATING LONG QT SYNDROME

This document relates to compounds useful for treating and preventing disorders associated with long QT syndrome such as cardiac arrhythmia, ventricular arrhythmia, hypertrophic cardiomyopathy, and congestive heart failure. Also provided herein are methods and materials for using such compounds to shorten myocardial repolarization time in a patient.

Chiral linker-bridged bis-N-heterocyclic carbenes: Design, synthesis, palladium complexes, and catalytic properties

A series of chiral bis(benzimidazolium) salts 10-19 with (1R,2R)-cyclohexene, (1R,2R)-diphenylethylene and (aR)-binaphthylene linkers have been designed and synthesized in 30-94% yield. Ten chiral bis(NHC) palladium complexes 20-28 have been synthesized and characterized by NMR, HRMS, elemental analysis and further confirmed by X-ray single crystal analysis. These bis(NHC)-Pd complexes showed obviously different catalytic properties in the asymmetric Suzuki-Miyaura coupling reactions. The (1R,2R)-cyclohexene-bridged bis(NHC)-Pd complex, (R,R)-23, achieved the highest yield of 90%, while complex (aR)-28, with a binaphthylene linker, showed the best enantioselectivity of 60 ee%. The structural analysis of these complexes suggested that such difference of catalytic performance has a close relationship with their coordination surroundings around metal centres.

HETEROCYCLIC COMPOUNDS AND THEIR USES

Substituted bicyclic heteroaryls and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (SLE), myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, Sjoegren's syndrome and autoimmune hemolytic anemia, allergic conditions including all forms of hypersensitivity, The present invention also enables methods for treating cancers that are mediated, dependent on or associated with p110δ activity, including but not restricted to leukemias, such as Acute Myeloid leukaemia (AML) Myelo-dysplastic syndrome (MDS) myelo-proliferative diseases (MPD) Chronic Myeloid Leukemia (CML) T-cell Acute Lymphoblastic leukaemia (T-ALL) B-cell Acute Lymphoblastic leukaemia (B-ALL) Non Hodgkins Lymphoma (NHL) B-cell lymphoma and solid tumors, such as breast cancer.

DIHYDROOROTATE DEHYDROGENASE INHIBITORS

The invention relates to compounds of formula (I) wherein R1, R2, X1, X2, Y, Ra, Rb, Q have the meanings given in claim 1. The compounds are useful e.g. in the treatment of autoimmune disorders, such as multiple sclerosis and also in the treatment of cancer disorders.

QUINOXALINE-BASED LXR MODULATORS

Disclosed are quinoxaline-based modulators of Liver X receptors (LXRs) and related methods. The modulators include compounds of formula (I): wherein: each of L1 and L2 is, independently, a bond, —O— or —NH—;R2 is C6/

Identification of phenylsulfone-substituted quinoxaline (WYE-672) as a tissue selective liver X-receptor (LXR) agonist

A series of phenyl sulfone substituted quinoxaline were prepared and the lead compound 13 (WYE-672) was shown to be a tissue selective LXR Agonist. Compound 13 demonstrated partial agonism for LXRβ in kidney HEK-293 cells but did not activate Gal4 LXRβ fusion proteins in huh-7 liver cells. Although 13 showed potent binding affinity to LXRβ (IC50 = 53 nM), it had little binding affinity for LXRα (IC50 > 1.0 μM) and did not recruit any coactivator/corepressor peptides in the LXRα multiplex assay. However, compound 13 showed good agonism in THP-1 cells with respect to increasing ABCA1 gene expression and good potency on cholesterol efflux in THP-1 foam cells. In an eight-week lesion study in LDLR -/- mice, compound 13 showed reduction of aortic arch lesion progression and no plasma or hepatic triglyceride increase. These results suggest quinoxaline 13 may have an improved biological profile for potential use as a therapeutic agent.

Substituted cycloalkylamine derivatives as modulators of chemokine receptor activity

The present application describes modulators of MCP-1 of formula (I): or pharmaceutically acceptable salt forms thereof, useful for the prevention of asthma, multiple sclerosis, artherosclerosis, and rheumatoid arthritis.